TrialThe European journal of health economics : HEPAC : health economics in prevention and care2022

Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study.

Hidetoshi Shibahara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.